<?xml version="1.0" encoding="UTF-8"?>
<ref id="B91-ijms-22-01591">
 <label>91.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zhao</surname>
    <given-names>J.J.</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Zhu</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Brooks</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Chu</surname>
    <given-names>Z.B.</given-names>
   </name>
   <name>
    <surname>Takada</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Ciccarelli</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Admin</surname>
    <given-names>S.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway</article-title>
  <source>Cancer Res.</source>
  <year>2014</year>
  <volume>74</volume>
  <fpage>1801</fpage>
  <lpage>1813</lpage>
  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-3311-T</pub-id>
  <pub-id pub-id-type="pmid">24599134</pub-id>
 </element-citation>
</ref>
